[go: up one dir, main page]

SV2009002858A - Nueva forma polimorfica y la forma amorfa de 5- cloro-n-([(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il]-metil)-2-tiofenocarboxamida - Google Patents

Nueva forma polimorfica y la forma amorfa de 5- cloro-n-([(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il]-metil)-2-tiofenocarboxamida

Info

Publication number
SV2009002858A
SV2009002858A SV2008002858A SV2008002858A SV2009002858A SV 2009002858 A SV2009002858 A SV 2009002858A SV 2008002858 A SV2008002858 A SV 2008002858A SV 2008002858 A SV2008002858 A SV 2008002858A SV 2009002858 A SV2009002858 A SV 2009002858A
Authority
SV
El Salvador
Prior art keywords
oxo
thiophenocarboxamide
morfolinil
amorphy
fenil
Prior art date
Application number
SV2008002858A
Other languages
English (en)
Inventor
Alfons Grunenberg
Jana Lenz
Chirstian R Thomas
Gerhard Arnold Braun
Birgit Keil
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37691766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2009002858(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE102005047564A external-priority patent/DE102005047564A1/de
Priority claimed from DE102005047563A external-priority patent/DE102005047563A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of SV2009002858A publication Critical patent/SV2009002858A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA INVENCIÓN SE REFIERE A UNA NUEVA FORMA POLIMÓRFICA V A LA FORMA AMORFA DE 5-CLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORFOLINIL)-FENIL]-1,3-OXAZOLIDIN-5-IL}-METIL)-2-TIOFENOCARBOXAMIDA, PROCEDIMIENTOS PARA SU PREPARACIÓN, FÁRMACOS QUE LA CONTIENEN ASÍ COMO A SU USO PARA EL CONTROL DE ENFERMEDADES
SV2008002858A 2005-10-04 2008-04-02 Nueva forma polimorfica y la forma amorfa de 5- cloro-n-([(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il]-metil)-2-tiofenocarboxamida SV2009002858A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005047564A DE102005047564A1 (de) 2005-10-04 2005-10-04 Amorphe Form von 5-Chlor-N-({(5S)2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid
DE102005047563A DE102005047563A1 (de) 2005-10-04 2005-10-04 Neue polymorphe Form von 5-Chlor-N-{(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid

Publications (1)

Publication Number Publication Date
SV2009002858A true SV2009002858A (es) 2009-07-28

Family

ID=37691766

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2008002858A SV2009002858A (es) 2005-10-04 2008-04-02 Nueva forma polimorfica y la forma amorfa de 5- cloro-n-([(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il]-metil)-2-tiofenocarboxamida

Country Status (22)

Country Link
US (1) US8188270B2 (es)
EP (1) EP1934208B1 (es)
JP (1) JP5416408B2 (es)
KR (1) KR101364400B1 (es)
AT (1) ATE502937T1 (es)
AU (1) AU2006299126B2 (es)
BR (1) BRPI0616801B8 (es)
CA (2) CA2624310C (es)
CR (1) CR9863A (es)
DE (1) DE502006009169D1 (es)
DK (1) DK1934208T3 (es)
EC (1) ECSP088341A (es)
IL (1) IL190204A (es)
MY (1) MY145616A (es)
NO (1) NO341632B1 (es)
NZ (1) NZ567092A (es)
PL (1) PL1934208T3 (es)
PT (1) PT1934208E (es)
RU (2) RU2578602C2 (es)
SG (1) SG166126A1 (es)
SV (1) SV2009002858A (es)
WO (1) WO2007039132A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
RU2578602C2 (ru) 2005-10-04 2016-03-27 Байер Интеллектуэль Проперти Гмбх Способ получения 5-хлор-n-(5s)-2-оксо-3-[4-(3-оксо-морфолинил)-фенил]-1,3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида в модификации ii (варианты)
DE102007028318A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Oxazolidinone zur Behandlung und Prophylaxe von Sepsis
CN101821260B (zh) * 2007-08-14 2013-07-31 康塞特医药品有限公司 取代的噁唑烷酮衍生物
JP5524852B2 (ja) * 2007-11-15 2014-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換アミド、それらの製造及び医薬品としての使用
DE102008028071A1 (de) 2008-06-12 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure
EP2303240A1 (en) 2008-07-08 2011-04-06 Ratiopharm GmbH Pharmaceutical compositions comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US20100168111A1 (en) * 2008-12-31 2010-07-01 Apotex Pharmachem Inc. Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
US7816355B1 (en) * 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
EP2266541A1 (en) 2009-06-18 2010-12-29 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising rivaroxaban
HRP20161617T4 (hr) 2009-06-18 2019-06-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Čvrsti farmaceutski sastav koji sadrži rivaroksaban
HUE057769T2 (hu) * 2009-07-31 2022-06-28 Krka D D Novo Mesto Eljárás rivaroxaban kristályosítására
US20120231076A1 (en) 2009-10-06 2012-09-13 Ratiopharm Gmbh Pharmaceutical compositions comprising rivaroxaban
EP2308472A1 (en) 2009-10-06 2011-04-13 ratiopharm GmbH Pharmaceutical compositions comprising rivaroxaban
EP2404920A1 (en) 2010-07-06 2012-01-11 Sandoz AG Crystalline form of Rivaroxaban dihydrate
US20130253187A1 (en) 2010-09-14 2013-09-26 Medichem, S.A. Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative
AT511045A1 (de) 2011-01-28 2012-08-15 Blum Gmbh Julius Möbelteil mit einer drehmomentübertragenden welle
WO2013098833A2 (en) 2011-09-08 2013-07-04 Cadila Healthcare Limited Processes and intermediates for preparing rivaroxaban
EP2573084A1 (en) 2011-09-22 2013-03-27 Enantia, S.L. Novel crystalline forms of rivaroxaban and processes for their preparation
HU230734B1 (hu) 2011-10-10 2017-12-28 EGIS Gyógyszergyár Nyrt Gyógyászati készítmény előállítására alkalmazható rivaroxaban kokristályok
WO2014016842A1 (en) * 2012-07-23 2014-01-30 Symed Labs Limited Amorphous coprecipitates of rivaroxaban
PT2935255T (pt) 2012-12-21 2017-11-21 D O O Farma Grs Processo para a preparação de rivaroxaban
ES2610020T3 (es) 2012-12-26 2017-04-25 Wanbury Limited Producto intermedio de rivaroxabán y preparación del mismo
EP2897619A4 (en) 2012-12-26 2016-08-17 Wanbury Ltd ALDEHYDE DERIVATIVE FROM SUBSTITUTED OXAZOLIDINONES
IN2014CH00290A (es) * 2014-01-23 2015-08-14 Symed Labs Ltd
WO2015176677A1 (en) * 2014-05-22 2015-11-26 Sunshine Lake Pharma Co., Ltd. Crystalline forms and amorphism of oxazolidinone compound
EA034656B1 (ru) * 2014-10-22 2020-03-03 Закляды Фармацеутычне Польфарма С.А Способ получения полиморфа ривароксабана
WO2020101587A1 (en) 2018-11-16 2020-05-22 Santa Farma İlaç Sanayi̇ A.Ş. Oral formulations comprising rivaroxaban
RU2020103395A (ru) * 2020-01-28 2021-07-28 Закрытое Акционерное Общество "Алмаз Фарм" L-, U-модификации 5-хлор-N-({ 5S)-2-оксо-3-[4-3-оксо-4-морфолинил)-фенил]-1,3-оксазолидин-5-ил} -метил)-2-тиофенкарбоксамида, сольват с диметилсульфоксидом, способы их получения, фармацевтические композиции на их основе, ингибирующие фактор Ха
GB202102575D0 (en) 2021-02-23 2021-04-07 Teva Pharmaceutical Industries Ltd Fixed-dose pharmaceutical compositions
GR1010231B (el) 2021-03-24 2022-05-10 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει ριβαροξαμπανη και μεθοδος παρασκευης αυτου
EP4201933A1 (en) 2021-12-23 2023-06-28 Zaklady Farmaceutyczne Polpharma S.A. Crystallisation process for rivaroxaban

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2811555A (en) 1955-05-02 1957-10-29 Eastman Kodak Co Reduction of 2-nitroso-5-diethylaminotoluene
US3279880A (en) 1965-07-12 1966-10-18 Eastman Kodak Co Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones
LU80081A1 (fr) 1977-08-26 1979-05-15 Delalande Sa Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique
US4128654A (en) 1978-02-10 1978-12-05 E. I. Du Pont De Nemours And Company 5-Halomethyl-3-phenyl-2-oxazolidinones
US4500519A (en) 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
HU190072B (en) 1983-03-11 1986-08-28 Biogal Gyogyszergyar,Hu Process for production of medical preparatives with sinergetic influence
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
NZ206600A (en) 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
ES8506659A1 (es) 1983-06-07 1985-08-01 Du Pont Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno.
EP0316594B1 (en) 1987-10-21 1993-09-29 The Du Pont Merck Pharmaceutical Company Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
US4977173A (en) 1987-10-21 1990-12-11 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5254577A (en) 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
CA2119556C (en) 1991-11-01 2004-07-06 Michael Robert Barbachyn Substituted aryl- and heteroaryl-phenyloxazolidinones
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US5349045A (en) 1993-01-26 1994-09-20 United States Surgical Corporation Polymer derived from cyclic amide and medical devices manufactured therefrom
DK0623615T3 (da) 1993-05-01 1999-12-13 Merck Patent Gmbh Adhæsionsreceptor-antagonister
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE4332384A1 (de) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
ES2163004T3 (es) 1995-02-03 2002-01-16 Upjohn Co Feniloxazolidinona sustituida por un anillo heteroaromatico como agente antimicrobiano.
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
DE19524765A1 (de) 1995-07-07 1997-01-09 Boehringer Mannheim Gmbh Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
CA2228647A1 (en) 1995-09-01 1997-03-13 Pharmacia & Upjohn Company Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA & UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
DE19601264A1 (de) 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
HRP970049A2 (en) 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
DE19604223A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
GB9614238D0 (en) 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
DK1175902T3 (da) 1996-07-15 2005-12-19 Sankyo Co Anvendelse CS-866 (olmesartan) til fremstillingen af et medikament til behandling af arteriosclerose
US5935724A (en) 1997-04-04 1999-08-10 Wilson Greatbatch Ltd. Electrochemical cell having multiplate electrodes with differing discharge rate regions
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
NZ501412A (en) 1997-05-30 2001-11-30 Upjohn Co Oxazolidinone antibacterial agents having a thiocarbonyl functionality
CA2294293A1 (en) 1997-07-11 1999-01-21 Pharmacia & Upjohn Company Thiadiazolyl and oxadiazolyl phenyl oxazolidinone antibacterial agents
DE19730847A1 (de) 1997-07-18 1999-01-28 Bayer Ag Tricyclisch substituierte Oxazolidinone
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
AU739055B2 (en) 1997-11-12 2001-10-04 Pharmacia & Upjohn Company Oxazolidinone derivatives and pharmaceutical compositions
US6083967A (en) 1997-12-05 2000-07-04 Pharmacia & Upjohn Company S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones
DE19755268A1 (de) 1997-12-12 1999-06-17 Merck Patent Gmbh Benzamidinderivate
EP1049682A1 (en) 1998-01-23 2000-11-08 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
HUP0101810A3 (en) 1998-01-27 2002-05-28 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl factor xa inhibitors and pharmaceutical compositions containing them
US20010029351A1 (en) 1998-04-16 2001-10-11 Robert Falotico Drug combinations and delivery devices for the prevention and treatment of vascular disease
EP1077718B1 (en) 1998-05-18 2002-08-14 PHARMACIA & UPJOHN COMPANY Enhancement of oxazolidinone antibacterial agents activity by arginine derivatives
DE19842753A1 (de) 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
PE20010851A1 (es) 1999-12-14 2001-08-17 Upjohn Co Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina
EP1242417A1 (en) 1999-12-21 2002-09-25 PHARMACIA & UPJOHN COMPANY Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
CA2395948A1 (en) * 1999-12-28 2001-07-05 Ajinomoto Co., Inc. Crystal of aspartame derivative
US6474231B1 (en) * 2000-07-26 2002-11-05 Heidelberger Druckmaschinen Ag Multi-color printing press with common blanket cylinder
DE10105989A1 (de) 2001-02-09 2002-08-14 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10110438A1 (de) 2001-03-05 2002-09-19 Bayer Ag Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
DE10110754A1 (de) 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115922A1 (de) 2001-03-30 2002-10-10 Bayer Ag Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10115945A1 (de) 2001-03-30 2002-10-02 Bayer Ag Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10134481A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10152460A1 (de) 2001-10-24 2003-05-08 Bayer Ag Stents
DE10238113A1 (de) 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
US20040024660A1 (en) 2002-08-05 2004-02-05 General Electric Company System and method for providing asset management and tracking capabilities
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004002044A1 (de) * 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
DE102004062475A1 (de) 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
RU2578602C2 (ru) 2005-10-04 2016-03-27 Байер Интеллектуэль Проперти Гмбх Способ получения 5-хлор-n-(5s)-2-оксо-3-[4-(3-оксо-морфолинил)-фенил]-1,3-оксазолидин-5-ил}-метил)-2-тиофенкарбоксамида в модификации ii (варианты)
DE102005047558A1 (de) 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005048824A1 (de) 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien

Also Published As

Publication number Publication date
RU2008116834A (ru) 2009-11-10
ATE502937T1 (de) 2011-04-15
JP5416408B2 (ja) 2014-02-12
CA2823159A1 (en) 2007-04-12
MY145616A (en) 2012-03-15
KR20080050465A (ko) 2008-06-05
SG166126A1 (en) 2010-11-29
CA2823159C (en) 2014-10-21
RU2429236C2 (ru) 2011-09-20
US20100152189A1 (en) 2010-06-17
CA2624310C (en) 2014-01-07
EP1934208A1 (de) 2008-06-25
BRPI0616801B1 (pt) 2020-08-25
IL190204A0 (en) 2008-11-03
AU2006299126B2 (en) 2012-06-28
IL190204A (en) 2014-08-31
RU2011115874A (ru) 2012-10-27
US8188270B2 (en) 2012-05-29
NO341632B1 (no) 2017-12-11
HK1125103A1 (en) 2009-07-31
BRPI0616801A2 (pt) 2011-06-28
CR9863A (es) 2009-02-19
ECSP088341A (es) 2008-06-30
PL1934208T3 (pl) 2011-09-30
NO20082059L (no) 2008-04-30
JP2009510140A (ja) 2009-03-12
BRPI0616801B8 (pt) 2021-05-25
AU2006299126A1 (en) 2007-04-12
NZ567092A (en) 2011-05-27
CA2624310A1 (en) 2007-04-12
DK1934208T3 (da) 2011-07-18
RU2578602C2 (ru) 2016-03-27
KR101364400B1 (ko) 2014-02-17
EP1934208B1 (de) 2011-03-23
PT1934208E (pt) 2011-06-01
WO2007039132A1 (de) 2007-04-12
DE502006009169D1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
SV2009002858A (es) Nueva forma polimorfica y la forma amorfa de 5- cloro-n-([(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il]-metil)-2-tiofenocarboxamida
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
ECSP088904A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
CL2011002697A1 (es) Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes
BR112012016398A2 (pt) Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
CL2008001994A1 (es) Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
BRPI0817562A2 (pt) derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis
UY30166A1 (es) Nuevas arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparación y su uso como medicamentos
PA8815201A1 (es) Compuestos heterociclicos
UY31136A1 (es) Oxazolidinonas sustituidas y su uso
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
CL2008002006A1 (es) Compuestos derivados de morfolin pirimidina, composicion farmaceutica, y su uso como inhibidores de la m-tor-quinasa para el tratamiento de l a inflamacion, cancer, enfermedades inmunes, enfermedad obstructiva pulmonar, enfermedad cardiovascular.
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
BRPI0813680A2 (pt) AGENTES DE iRNA, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO OS MESMOS, BEM COMO SEU USO.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
UY30163A1 (es) Nuevas ariltienopirimidinonas sustituidas con azaciclilo, procedimiento para su preparación y su uso como medicamentos
UY30165A1 (es) Nuevas arildihidroisoquinolinonas sustituidas con aminolcoholes, procedimiento para su preparación y su uso como medicamentos
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
EP2193795A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING LATANOPROST
NI201000173A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre.